WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014190090) GENETIC SIGNATURE OF VULNERABILITY TO INHIBITORS OF BASE EXCISION REPAIR (BER) IN CANCER
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/190090    International Application No.:    PCT/US2014/039033
Publication Date: 27.11.2014 International Filing Date: 21.05.2014
IPC:
C12Q 1/68 (2006.01)
Applicants: DIGNITY HEALTH [US/US]; 350 West Thomas Road Phoenix, Arizona 85013 (US)
Inventors: MEHTA, Shwetal V.; (US).
BERENS, Michael E.; (US).
DHRUV, Harshil Dineshkumar; (US)
Agent: SENN, Sean; Nixon Peabody LLP Gas Company Tower 555 West Fifth Street, 46th Floor Los Angeles, California 90013 (US)
Priority Data:
61/825,962 21.05.2013 US
Title (EN) GENETIC SIGNATURE OF VULNERABILITY TO INHIBITORS OF BASE EXCISION REPAIR (BER) IN CANCER
(FR) SIGNATURE GÉNÉTIQUE DE LA VULNÉRABILITÉ AUX INHIBITEURS DE LA RÉPARATION PAR EXCISION DES BASES (BER) EN ONCOLOGIE
Abstract: front page image
(EN)The invention relates to the identification of genetic signatures and expression profiles that are a part of the Base Excision Repair (BER) pathway, a major DNA repair pathway that modifies base lesions. In one embodiment, the present invention provides a method of determining responsiveness of treatment by BER inhibitors for malignant glioma by determining the presence of a low level of expression of Apex 1, a low level of expression of Apex 2, and a high level of expression of MPG.
(FR)L'invention concerne l'identification de signatures génétiques et de profils d'expression qui appartiennent au chemin de réparation par excision des bases ou "BER" (Base Excision Repair), un important chemin de réparation de l'ADN qui modifie les lésions des bases. Dans un mode de réalisation, l'invention propose un procédé permettant de déterminer la faculté de réponse au traitement par des inhibiteurs de BER dans le cas de gliomes malins, et ce, en déterminant la présence d'un faible niveau d'expression d'Apex 1, d'un faible niveau d'expression d'Apex 2, et d'un niveau élevé d'expression de la MPG.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)